Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 200

1.

Is the Dexamethasone-Sparing Strategy Ready For Cisplatin? Too Early For an Answer.

Celio L, Bonizzoni E, Aapro M.

J Clin Oncol. 2018 Sep 10;36(26):2741-2742. doi: 10.1200/JCO.2018.78.8109. Epub 2018 May 25. No abstract available.

PMID:
29799771
2.

De vrais espoirs et de sérieuses préoccupations.

Peters S, Dietrich PY, Aapro M.

Rev Med Suisse. 2018 May 16;14(607):1011-1012. French. No abstract available.

PMID:
29767891
3.

Development and 10-year history of a biosimilar: the example of Binocrit®.

Aapro M, Krendyukov A, Höbel N, Seidl A, Gascón P.

Ther Adv Med Oncol. 2018 Apr 17;10:1758835918768419. doi: 10.1177/1758835918768419. eCollection 2018. Review.

4.

Searching for perfection: further progress in management of chemotherapy-induced nausea and vomiting-concluding thoughts.

Aapro M.

Support Care Cancer. 2018 Mar;26(Suppl 1):35-37. doi: 10.1007/s00520-018-4121-5. Epub 2018 Mar 19. No abstract available.

5.

Searching for perfection: further progress in management of chemotherapy-induced nausea and vomiting-introduction.

Aapro M.

Support Care Cancer. 2018 Mar;26(Suppl 1):3-4. doi: 10.1007/s00520-018-4147-8. Epub 2018 Mar 19. No abstract available.

6.

CINV: still troubling patients after all these years.

Aapro M.

Support Care Cancer. 2018 Mar;26(Suppl 1):5-9. doi: 10.1007/s00520-018-4131-3. Epub 2018 Mar 19.

7.

Searching for perfection: further progress in management of chemotherapy-induced nausea and vomiting-CME information.

Aapro M, Clemons M, Schwartzberg L, Warr D.

Support Care Cancer. 2018 Mar;26(Suppl 1):1-2. doi: 10.1007/s00520-018-4122-4. Epub 2018 Mar 19. No abstract available.

PMID:
29556807
8.

Correction to: Epoetin Biosimilars in the Treatment of Chemotherapy-Induced Anemia: 10 Years' Experience Gained.

Aapro M, Krendyukov A, Schiestl M, Gascón P.

BioDrugs. 2018 Apr;32(2):137-138. doi: 10.1007/s40259-018-0268-3.

PMID:
29492906
9.

Epoetin Biosimilars in the Treatment of Chemotherapy-Induced Anemia: 10 Years' Experience Gained.

Aapro M, Krendyukov A, Schiestl M, Gascón P.

BioDrugs. 2018 Apr;32(2):129-135. doi: 10.1007/s40259-018-0262-9. Review. Erratum in: BioDrugs. 2018 Feb 28;:.

10.

Continuity and diversity.

Aapro M.

Crit Rev Oncol Hematol. 2018 Jan;121:A2. doi: 10.1016/j.critrevonc.2017.12.001. Epub 2017 Dec 7. No abstract available.

PMID:
29242024
11.

MONITOR-GCSF DLBCL subanalysis: Treatment patterns/outcomes with biosimilar filgrastim for chemotherapy-induced/febrile neutropenia prophylaxis.

Gascón P, Krendyukov A, Höbel N, Aapro M.

Eur J Haematol. 2018 Mar;100(3):241-246. doi: 10.1111/ejh.13002. Epub 2017 Dec 29.

PMID:
29171913
12.

Recent developments in the clinical pharmacology of rolapitant: subanalyses in specific populations.

Rapoport BL, Aapro M, Chasen MR, Jordan K, Navari RM, Schnadig I, Schwartzberg L.

Drug Des Devel Ther. 2017 Sep 5;11:2621-2629. doi: 10.2147/DDDT.S133943. eCollection 2017. Review.

13.

Refining the role of pegfilgrastim (a long-acting G-CSF) for prevention of chemotherapy-induced febrile neutropenia: consensus guidance recommendations.

Aapro M, Boccia R, Leonard R, Camps C, Campone M, Choquet S, Danova M, Glaspy J, Hus I, Link H, Sliwa T, Tesch H, Valero V.

Support Care Cancer. 2017 Nov;25(11):3295-3304. doi: 10.1007/s00520-017-3842-1. Epub 2017 Aug 25. Review.

14.

Supportive care for patients undergoing immunotherapy.

Rapoport BL, van Eeden R, Sibaud V, Epstein JB, Klastersky J, Aapro M, Moodley D.

Support Care Cancer. 2017 Oct;25(10):3017-3030. doi: 10.1007/s00520-017-3802-9. Epub 2017 Jul 13.

PMID:
28707167
15.

Identifying critical steps towards improved access to innovation in cancer care: a European CanCer Organisation position paper.

Aapro M, Astier A, Audisio R, Banks I, Bedossa P, Brain E, Cameron D, Casali P, Chiti A, De Mattos-Arruda L, Kelly D, Lacombe D, Nilsson PJ, Piccart M, Poortmans P, Riklund K, Saeter G, Schrappe M, Soffietti R, Travado L, van Poppel H, Wait S, Naredi P.

Eur J Cancer. 2017 Sep;82:193-202. doi: 10.1016/j.ejca.2017.04.014. Epub 2017 Jul 7.

16.

L’accès à l’innovation.

Aapro M, Dietrich PY, Peters S.

Rev Med Suisse. 2017 May 17;13(563):1027. French. No abstract available.

PMID:
28636291
17.

The MAGIC survey in hormone receptor positive (HR+), HER2-negative (HER2-) breast cancer: When might multigene assays be of value?

Aapro M, De Laurentiis M, Rea D, Bargallo Rocha JE, Elizalde R, Landherr L, Linderholm B, Mamounas E, Markopoulos C, Neven P, Petrovsky A, Rouzier R, Smit V, Svedman C, Schneider D, Thomssen C, Martin M.

Breast. 2017 Jun;33:191-199. doi: 10.1016/j.breast.2017.01.012. Epub 2017 Apr 22.

PMID:
28441617
18.

Management of Aromatase Inhibitor-Associated Bone Loss (AIBL) in postmenopausal women with hormone sensitive breast cancer: Joint position statement of the IOF, CABS, ECTS, IEG, ESCEO IMS, and SIOG.

Hadji P, Aapro MS, Body JJ, Gnant M, Brandi ML, Reginster JY, Zillikens MC, Glüer CC, de Villiers T, Baber R, Roodman GD, Cooper C, Langdahl B, Palacios S, Kanis J, Al-Daghri N, Nogues X, Eriksen EF, Kurth A, Rizzoli R, Coleman RE.

J Bone Oncol. 2017 Mar 23;7:1-12. doi: 10.1016/j.jbo.2017.03.001. eCollection 2017 Jun. Review.

19.

Radiopharmaceuticals in the elderly cancer patient: Practical considerations, with a focus on prostate cancer therapy: A position paper from the International Society of Geriatric Oncology Task Force.

Prior JO, Gillessen S, Wirth M, Dale W, Aapro M, Oyen WJG.

Eur J Cancer. 2017 May;77:127-139. doi: 10.1016/j.ejca.2017.01.030. Epub 2017 Apr 7.

20.

Efficacy of NEPA (netupitant/palonosetron) across multiple cycles of chemotherapy in breast cancer patients: A subanalysis from two phase III trials.

Rugo HS, Rossi G, Rizzi G, Aapro M.

Breast. 2017 Jun;33:76-82. doi: 10.1016/j.breast.2017.02.017. Epub 2017 Mar 10.

Supplemental Content

Loading ...
Support Center